RxDoctor Payments DataLook up a doctor →

Brandon Hansen, PA

Medical · Riverton, UTNPI 1467735621

Payments from drug & device makers

$10,160in general payments, 2019–2025

Across 572 payments — averaging $17.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • AstraZeneca$706
  • Lilly USA, LLC$684
  • Boehringer Ingelheim$489
  • Novo Nordisk$432
  • Amgen$392
  • plus $5K from 52 others

What the payments were for

  • Food & beverage$10,160100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,160 in reported general payments places this provider in the 95th percentile of 263 medical providers in Utah.

See all medical providers in Utah

Medicare billing

Part B allowed, 2024
$25,450
Medicare patients
88
Services billed
695

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide70$92,752
EliquisApixaban55$49,575
JardianceEmpagliflozin45$46,991
TrulicityDulaglutide22$39,596
FarxigaDapagliflozin Propanediol56$37,070
MounjaroTirzepatide22$29,548
XareltoRivaroxaban24$22,200
JanuviaSitagliptin Phosphate13$16,551
LinzessLinaclotide15$12,647
Xigduo XrDapaglifloz Propaned/Metformin13$12,196
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$7,123
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$5,484
Omeprazole193$4,276
Gabapentin129$3,981
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$3,558

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$432$92,75270 claims
Lilly USA, LLCTrulicity, Mounjaro$684$69,14444 claims
Boehringer IngelheimJardiance, Stiolto Respimat$489$52,47456 claims
PfizerEliquis$325$49,57555 claims
AstraZenecaFarxiga$706$37,07056 claims
Johnson & JohnsonXarelto$58$22,20024 claims
MerckJanuvia$120$16,55113 claims
AbbVieLinzess, Synthroid$2,537$14,15828 claims
Sanofi-aventis U.S. LLCLantus$96$1,12911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 263 medical providers in Utah.

Other medical in Riverton

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →